Dissolution parameters for sodium diclofenac-containing hypromellose matrix tablet

被引:20
作者
Mourao, Samanta C. [1 ,2 ]
da Silva, Cristiane [1 ]
Bresolin, Tania M. B. [1 ]
Serra, Cristina H. R. [2 ]
Porta, Valentina [2 ]
机构
[1] Univ Vale Itajai, UNIVALI, Curso Farm, Nucleo Invest Quimicofarmaceut NIQFAR, BR-88302202 Itajai, SC, Brazil
[2] Univ Sao Paulo, Fac Ciencias Farmaceut, BR-05508900 Sao Paulo, Brazil
关键词
Sodium diclofenac; Dissolution assay; Dissolution kinetics; Hypromellose; CONTROLLED-RELEASE; DRUG-RELEASE; IN-VITRO; DELIVERY; HPMC;
D O I
10.1016/j.ijpharm.2009.11.022
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sodium diclofenac (SD) release from dosage forms has been studied under different conditions. However, no dissolution method that is discriminatory enough to reflect slight changes in formulation or manufacturing process, and which could be effectively correlated with the biological properties of the dosage form, has been reported. This study sought to develop three different formulae of SD-containing matrix tablets and to determine the effect of agitation speed in its dissolution profiles. F1, F2 and F3 formulations were developed using hypromellose (10, 20 and 30%, respectively for F1, F2 and F3) and other conventional excipients. Dissolution tests were carried out in phosphate buffer pH 6.8 at 37 degrees C using apparatus 11 at 50, 75 or 100 rpm. Dissolution efficiency (DE), T-50 and T-90 were determined and plotted as functions of the variables agitation speed and hypromellose concentration. Regarding DE, F2 showed more sensitivity to variations in agitation speed than F1 and F3. Increasing hypromellose concentration reduced DE values, independent of agitation speed. Analysis of T-50 and T-90 suggests that F1 is less sensitive to variations in agitation speed than F2 and F3. Most discriminatory dissolution conditions were observed at 50 rpm. Results suggest that the comparison of dissolution performance of SD matrix tablets should take into account polymer concentration and agitation conditions. (C) 2009 Published by Elsevier B.V.
引用
收藏
页码:201 / 207
页数:7
相关论文
共 30 条
[1]  
Abdou H.M., 1989, Dissolution, Bioavailability Bioequivalence, P145
[2]  
[Anonymous], 1988, FARMACOPEIA BRASILEI
[3]   Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate [J].
Avachat, Amelia ;
Kotwal, Vikram .
AAPS PHARMSCITECH, 2007, 8 (04)
[4]   Current perspectives in dissolution testing of conventional and novel dosage forms [J].
Azarmi, Shirzad ;
Roa, Wilson ;
Lobenberg, Raimar .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 328 (01) :12-21
[5]  
BANAKAR UV, 1992, PHARM DISSOLUTION TE, P307
[6]  
Bravo SA, 2002, J PHARM PHARM SCI, V5, P213
[7]  
Colombo, 2000, Pharm Sci Technol Today, V3, P198, DOI 10.1016/S1461-5347(00)00269-8
[8]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[9]   A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System [J].
Dokoumetzidis, Aristides ;
Macheras, Panos .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 321 (1-2) :1-11
[10]   Regulatory aspects of drug dissolution from a European perspective [J].
Graffner, Christina .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 29 (3-4) :288-293